Plain language summary of the NefIgArd trial: Nefecon for treating patients with immunoglobulin A nephropathy

This Plain Language Summary of publication article (PLSP) from Future Rare Diseases covers the NefIgArd clinical trial results, which studied Nefecon, a new treatment for immunoglobulin A nephropathy (IgAN), a kidney disease caused by a buildup of a specific antibody. IgAN leads to kidney inflammation and damage, potentially causing kidney failure. Nefecon contains budesonide and targets the disease process in the small intestine.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial’ and was published in The Lancet.

Visit The Lancet using the link to read the original article.

• budesonide
• gut
• IgAN
• immunoglobulin A
• kidney
• kidney damage
• kidney failure
• lay summary
• Nefecon
• nephropathy
• plain language summary
• small intestine